New model aims to make leukemia treatment safer and more effective
NCT ID NCT07499349
First seen Apr 06, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study uses data from about 475 children with acute lymphoblastic leukemia (ALL) who received the drug Erwinase. Researchers will build a computer model to understand how the drug moves through the body, with the goal of finding the best dose to kill cancer cells while avoiding side effects like high ammonia levels. The study does not test a new treatment but analyzes existing data to improve future dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
RECRUITINGAarhus, Denmark
Conditions
Explore the condition pages connected to this study.